Last Updated on: 07 July, 2024|Author: Getaka | Social:
Stock Ticker - BSE: 543904 | NSE: MANKIND
Fundamental Analysis of Mankind Pharma Ltd
Basic Stock Data
Last Updated: July 6, 2024, 11:12 am
Market Cap
85,650 Cr.
Current Price
2,138
High / Low
2,490/1,680
Stock P/E
47.0
Book Value
240
Dividend Yield
0.00 %
ROCE
26.1 %
ROE
21.0 %
Face Value
1.00
PEG Ratio
3.42
Competitors of Mankind Pharma Ltd
Stock Name
Market Cap
Current Price
High / Low
Stock P/E
Book Value
Dividend Yield
ROCE
ROE
Face Value
Industry Average
0 Cr
0
0
0
0%
0%
0%
0
Quarterly Result
Month
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Sales
1,645
2,061
2,258
1,936
1,872
2,300
2,453
2,359
2,153
Expenses
1,336
1,641
1,735
1,563
1,491
1,761
1,818
1,755
1,605
Operating Profit
309
420
522
374
381
539
635
603
547
OPM %
19%
20%
23%
19%
20%
23%
26%
26%
25%
Other Income
8
19
69
32
42
57
58
67
84
Interest
11
9
8
9
1
2
4
4
4
Depreciation
36
65
66
71
67
69
77
90
82
Profit before tax
270
365
517
326
355
526
612
576
545
Tax %
20%
18%
19%
24%
21%
22%
23%
15%
17%
Net Profit
217
298
420
249
281
409
473
487
454
EPS in Rs
5.43
7.44
10.49
6.21
7.01
10.22
11.80
12.16
11.34
Last Updated: June 9, 2024, 6:20 pm
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 25, 2024, 10:22 pm
Month
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Sales
3,918
3,829
4,794
5,523
7,486
8,127
9,265
Expenses
3,141
3,124
3,550
4,151
5,644
6,429
6,940
Operating Profit
778
705
1,244
1,372
1,842
1,698
2,325
OPM %
20%
18%
26%
25%
25%
21%
25%
Other Income
209
64
94
154
200
163
267
Interest
18
40
11
8
48
28
15
Depreciation
28
38
62
78
123
270
318
Profit before tax
941
691
1,265
1,440
1,871
1,563
2,260
Tax %
26%
26%
24%
25%
26%
20%
19%
Net Profit
694
514
958
1,084
1,389
1,248
1,823
EPS in Rs
17.33
12.83
23.92
27.07
34.68
31.16
45.52
Dividend Payout %
0%
0%
32%
0%
0%
0%
0%
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
YoY Net Profit Growth (%)
-25.94%
86.38%
13.15%
28.14%
-10.15%
46.07%
Change in YoY Net Profit Growth (%)
0.00%
112.32%
-73.23%
14.98%
-38.29%
56.22%
Growth
Compounded Sales Growth
10 Years:
%
5 Years:
19%
3 Years:
19%
TTM:
14%
Compounded Profit Growth
10 Years:
%
5 Years:
29%
3 Years:
20%
TTM:
50%
Stock Price CAGR
10 Years:
%
5 Years:
%
3 Years:
%
1 Year:
27%
Return on Equity
10 Years:
%
5 Years:
22%
3 Years:
20%
Last Year:
21%
Last Updated: July 2, 2024, 12:20 pm
Balance Sheet
Last Updated: May 27, 2024, 4:06 am
Month
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Equity Capital
40
40
40
40
40
40
40
Reserves
2,957
3,025
3,611
4,694
6,500
7,744
9,584
Borrowings
360
190
3
101
688
5
9
Other Liabilities
652
596
877
1,045
1,710
1,583
1,785
Total Liabilities
4,009
3,851
4,531
5,880
8,939
9,371
11,418
Fixed Assets
534
778
945
987
2,927
3,142
3,479
CWIP
322
211
148
166
387
495
113
Investments
1,402
1,698
1,784
2,397
2,526
3,102
4,430
Other Assets
1,751
1,164
1,655
2,330
3,100
2,632
3,396
Total Assets
4,009
3,851
4,531
5,880
8,939
9,371
11,418
Reserves and Borrowings Chart
Cash Flow
Month
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Cash from Operating Activity
540
537
960
983
821
1,799
1,983
Cash from Investing Activity
-516
-306
-396
-1,127
-1,360
-1,041
-1,919
Cash from Financing Activity
8
-240
-559
89
579
-710
-9
Net Cash Flow
31
-9
5
-55
40
48
55
Free Cash Flow
Month
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Free Cash Flow
418.00
515.00
-2.00
-100.00
-687.00
-4.00
-7.00
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
Undervalued: 13.01% compared to the current price 2138
Intrinsic Value: 2,748.00
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.
Undervalued: 28.53% compared to the current price ₹2138
Last 5 Year EPS CAGR: 13.73%
*Investments are subject to market risks
Strength and Weakness
Strength
Weakness
The stock has a high average ROCE of 23.67%, which is a positive sign.
The company has higher reserves (5,445.00 cr) compared to borrowings (193.71 cr), indicating strong financial stability.
The company has shown consistent growth in sales (5.57 cr) and profit (234.00 cr) over the years.
The stock has a high average Working Capital Days of 54.83, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 50.83, which may not be favorable.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mankind Pharma Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 20.43% (Industry Average ROE: %)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
✗ Stock P/E: 47.0 (Industry average Stock P/E: )
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.02
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:★★★★☆
About the Company
Pharmaceuticals
INDUSTRY
ADDRESS
CONTACT
208, Okhla Industrial Estate, New Delhi Delhi 110020
Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Mankind Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
